
ResMed (RMD) Stock Forecast & Price Target
ResMed (RMD) Analyst Ratings
Bulls say
ResMed is a fundamentally strong company with a positive outlook due to its strong financial performance, including revenue growth and gross margin expansion, and its investments in digital health technology to differentiate itself from competitors. However, potential concerns about competition in international markets and continued high opex levels may give some investors pause. The company's recent earnings beat and increasing guidance for FY26 are positive indicators, but the potential impact of GLP-1 drugs on PAP volumes could be a medium-term disruption.
Bears say
ResMed is facing several risks and challenges that could negatively impact its stock, including potential disruptions in its key revenue driver, CPAP technology, from the emergence of GLP-1 therapeutics. Additionally, despite recent acquisitions and a focus on digital health, competition and market saturation may limit the company's ability to gain market share. However, there may be potential upside from the growing market for sleep apnea and other chronic diseases, as well as positive surprises from new technology and market opportunities. Investors should keep an eye on utilization rates for CPAP technology and the company's ability to differentiate itself in a competitive landscape.
This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.
ResMed (RMD) Analyst Forecast & Price Prediction
Start investing in ResMed (RMD)
Order type
Buy in
Order amount
Est. shares
0 shares